Skip to main content
EyeGene,Inc logo

EyeGene,Inc — Investor Relations & Filings

Ticker · 185490 ISIN · KR7185490000 KO Professional, scientific and technical activities
Open in API
Filings indexed 314 across all filing types
Latest filing 2025-02-10 Earnings Release
Country KR South Korea
Listing KO 185490

About EyeGene,Inc

https://eyegene.co.kr/en/

EyeGene, Inc. is a clinical-stage biopharmaceutical company that researches and develops innovative therapeutics, with a primary focus on gene and cell therapy for age-related diseases. The company's pipeline includes EG-Mirotin, a treatment candidate for non-proliferative diabetic retinopathy and dry age-related macular degeneration. EyeGene is also developing preventive vaccines, such as EG-HPV for cervical cancer, utilizing its proprietary EG-Vac adjuvant system to enhance vaccine efficacy. The company is dedicated to creating transformative treatments by advancing biomedical science.

Recent filings

Filing Released Lang Actions
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Eutilex/Eyegene) disclosing a significant change in financial structure (30% or more change in profit/loss). This type of disclosure is a standard regulatory requirement in the Korean market (DART system) for reporting preliminary financial results or significant changes before the final audit report is finalized. It fits the definition of an Earnings Release (ER) as it provides key financial highlights and the reasons for the variance. FY 2024
2025-02-10 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement from the company '아이진' (Eyegene) regarding the setting of a record date for the upcoming 25th Annual General Meeting. It specifies the record date (2024-12-31) and the purpose (determining shareholders for the AGM). Since it is a brief regulatory notice regarding meeting preparation rather than the meeting materials themselves or a full report, it falls under the general regulatory filing category.
2024-12-10 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '아이진 주식회사' (EyeGene Inc.) covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial and business information, including company overview, management, capital structure, and business operations. This aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-14 Korean
투자판단관련주요경영사항(임상시험계획승인신청) (4가 수막구균 접합백신 ‘EG-MCV4'의 국내 임상 3상 임상시험계획 승인 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Eutilex/Eyegene) regarding the submission of a Phase 3 clinical trial application to the Ministry of Food and Drug Safety (MFDS). It details the clinical trial name, purpose, methodology, and target population. Since this is a specific regulatory disclosure regarding clinical trial status and does not fit into categories like Annual Reports, Earnings Releases, or M&A, it is classified as a general Regulatory Filing (RNS).
2024-11-01 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options). It details the issuance of stock options to an executive, including the number of shares, exercise price, and valuation methodology. In the context of Korean corporate filings (DART system), this is a specific regulatory disclosure regarding capital structure changes and executive compensation incentives. Since it does not fit into the specific categories of 'Director's Dealing' (which usually refers to market trades) or 'Remuneration Information' (which refers to annual compensation reports), and it is a mandatory regulatory disclosure, it falls under the 'Regulatory Filings' (RNS) category.
2024-09-30 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company '아이진 주식회사' (EyeGene Inc.) covering the period from January 1, 2024, to June 30, 2024. It contains comprehensive financial and business information, including company overview, management discussion, and business operations, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.